Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CHPA comments on identity testing

This article was originally published in The Tan Sheet

Executive Summary

The Consumer Healthcare Products Association requests a 60-day extension to the comment period for FDA's interim final rule on a petition to request exemption from 100% identity testing of dietary ingredients in a letter to FDA Aug. 9. "CHPA and its members feel that additional time is needed to adequately respond to the Federal Register notice," the association notes. The IFR was published June 25 and will be effective Aug. 24 (1"The Tan Sheet" July 23, 2007, p. 3). In a separate same-day filing, the trade group also requests a 60-day extension of the comment period for FDA's draft guidance for industry on an evidence-based review system for the scientific evaluation of health claims. The group feels "additional time is needed to adequately prepare" its comments; if the agency grants CHPA's request, the new comment deadline would be Nov. 6...

You may also be interested in...

GMP Interim Final Rule Sets Bar High For 100% Testing Exemption – Experts

Firms "rarely" will meet the scientific rationale FDA included in an interim final rule to substantiate petitions for exemption from 100 percent ingredient identity testing required in the dietary supplement good manufacturing practices, according to food and drug law expert Scott Bass

The ICER Process: Allergan Engagement Improves Cost Effectiveness Rating For Ubrelvy

ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.

US FDA’s 2020 Approvals: A Deep Pipeline, And More Of The Expected

Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts